Surgical Oncology Research and Cancer Immunotherapy Fellowships

The Fellowships in Surgical Oncology Research and Cancer Immunotherapy at the National Cancer Institute (NCI) encompass two time-honored programs combining bench-side research in surgical oncology with training in clinical research through direct patient care.  The unique environment of the Clinical Center at the National Institutes of Health (NIH) allows for direct bedside-to-bench and bench-to-bedside translational research under the direction of world leaders in surgical oncology.

Two- and three-year research programs are available.

Description of Fellowships

Infographic showing time breakdowns the Surgical Oncology Research Fellowship

Surgical Oncology Research Fellowship

This 2-year fellowship includes 18 months of bench laboratory experience in one of the many NCI laboratories and 6 months of clinical rotations over three surgical oncology subspecialties. Clinical research opportunities are available over the entire 2-year period. Additional optional research years may be available.

Fellowship in Cancer Immunotherapy

This 3-year fellowship incorporates an additional year of clinical experience in the management of patients undergoing cell-based cancer immunotherapy developed in the Surgery Branch of the NCI. Basic science experience is dedicated to work in one of the multiple immunotherapy laboratories within the NCI and participation in this fellowship is complemented by additional didactic opportunities in cancer immunotherapy.

Fellowship Directors

Jeremy L. Davis, M.D.
Program Director

Jonathan M. Hernandez, M.D.
Assistant Program Director

Program Administrators

Ms. Joanna Lamot
Ph: 240.858.3731

Ms. Danielle Stewart
Ph: 240.858.3875


All CCR residents and clinical fellows train at the 240-bed NIH Clinical Center, internationally recognized as the premier hospital dedicated to translational research and clinical care. Elective rotations offer residents and clinical fellows the opportunity to have direct experience in the care of patients enrolled in investigational protocols in the disciplines allergy and immunology, anatomic pathology, critical care medicine/internal medicine, hematopathology, infectious diseases, medical genetics, and transfusion medicine. Participants will have first-hand exposure to the design, conduct, and management of clinical trials. 

All of CCR’s clinical training programs are part of Graduate Medical Education at NIH

Surgical Oncology Research Fellows 2018

How to Apply

The Surgical Oncology Fellowship commences on July 1st. Applications are accepted throughout the year. A statement of interest in the program, curriculum vitae and three (3) letters of recommendation can be sent directly to the Program Administrator. Alternatively, interested applicants may submit materials through the NIH Graduate Medical Education page.

For More Information

Please contact the Program Administrator, Joanna Lamot, for additional information.

Application materials, including CV, letters of recommendation and cover letter, may be sent directly to the Program Administrator.

View Fellowship Program Details

Fellowship Faculty

Name Position Specialty
Dr. Jeremy Davis Program Director Surgical Oncology
Dr. Jonathan Hernandez Assistant Program Director Surgical Oncology
Dr. Steven Rosenberg Chief, Surgery Branch Cancer Immunotherapy
Dr. David Schrump Senior Investigator Thoracic Surgery
Dr. Chuong Hoang Investigator Thoracic Surgery
Dr. Richard Sherry Associate Research Physician Cancer Immunotherapy
Dr. James Yang Senior Investigator Cancer Immunotherapy
Dr. Stephanie Goff Associate Research Physician Cancer Immunotherapy
Dr. Naris Nilubol Assistant Clinical Investigator Endocrine Surgery
Dr. Samira Sadowski Assistant Clinical Investigator Endocrine Surgery

Didactics and Clinical Research

Multiple educational conferences highlighting the principles of clinical research are integrated throughout the fellowship experience.

Surgical Oncology Fellows’ Educational Conference

Weekly lecture series throughout the academic year with presentations from NCI faculty addressing the fundamentals of clinical study design and interpretation, design and progress of current NCI clinical trials, and fellow-led debates on current questions in surgical oncology.

Weekly Clinical Conference

Weekly departmental meeting similar to a Grand Rounds and Morbidity/Mortality conference focusing on management of challenging cases of the NCI Surgical Oncology Clinical Service.

Surgical Oncology Fellows’ Journal Club

Monthly, fellow-run Surgical Oncology Journal Club focusing on seminal and current studies across general, thoracic and endocrine surgical oncology.

Surgical Oncology Clinical Research Meeting

Bi-monthly, clinical research think-tank focused on the development and support of clinical research projects for fellows.

Multidisciplinary Oncology Meetings

Multiple clinically and translationally oriented meetings focus on care of complex general surgical oncology, thoracic and endocrine diseases:

  • NIH Foregut Team manages patients with tumors of the esophagus, stomach, liver, pancreas and bile ducts
  • Thoracic Tumor Board
  • Endocrine Oncology Tumor Board

NIH-wide Lecture and Educational Opportunities

Diverse, NIH-wide lecture series focusing on basic science, translational and clinical work as well as traditional classroom educational opportunities in basic and clinical science available through the NIH Graduate School.

Recent Alumni

Complex General Surgical Oncology

  • Chenwi Ambe, MD
    Moffitt Cancer Center

  • Reed Ayabe, MD
    LAC Harbor UCLA Medical Center

  • Joal Beane, MD

  • Jessica Crystal, MD
    Cedars Sinai Medical Center, Los Angeles, CA

  • Jeremy Davis, MD
    Memorial Sloan Kettering Cancer Center

  • Lindy Davis, MD
    Roswell Park Cancer Institute

  • Timothy Frankel, MD
    Memorial Sloan Kettering Cancer Center

  • Danielle Hari, MD
    John Wayne Cancer Institute, Santa Monica, CA

  • Jenny Hong, MD
    Cedars Sinai Medical Center, Los Angeles, CA

  • Young Ki Hong, MD
    University of Louisville

  • Kshama Jaiswal, MD
    National Cancer Medical Center, Dallas, TX
    Memorial Sloan Kettering Cancer Center

  • Mio Kitano, MD
    The Ohio State University

  • Mei Li Kwong, MD
    Loma Linda University

  • Russell Langan, MD
    Memorial Sloan Kettering Cancer Center

  • John Mullinax, MD
    Moffitt Cancer Center

  • Peter A. Prieto, MD
    MD Anderson Cancer Center

  • Luke Rothermel, MD
    Moffitt Cancer Center

  • Nicholas Schaub, MD
    University of North Carolina, Chapel Hill

  • Jennifer Tseng, MD
    University of Chicago

Cardiothoracic Surgery

  • Scott Atay, MD
    MD Anderson Cancer Center

  • Clinton Kemp, MD
    The Johns Hopkins University

  • Kiran Lagisetty, MD
    University of Michigan

  • R. Taylor Ripley, MD
    Memorial Sloan Kettering Cancer Center

  • Christopher Scott, MD
    Duke University

  • Trevor Upham, MD
    University of California, San Diego

Breast Surgical Oncology

  • Kshama Jaiswal, MD
    National Cancer Medical Center, Dallas, TX
    Memorial Sloan Kettering Cancer Center

  • Tristen Park, MD
    Duke University

  • Sarah Treter, MD
    Yale University

Endocrine Surgery

  • Yasmine Assadipour, MD
    University of California, Los Angeles

  • Aarti Mathur, MD
    The Johns Hopkins University

  •  Reza Rahbari, MD
    Cleveland Clinic

  • Syed Shah, MD
    Duke University

  • Ashley Stewart, MD
    MD Anderson Cancer Center

Hepatobiliary Surgery

  • Rachel Beard, MD
    University of Pittsburg Medical Center

  • Simon Turcotte, MD
    Memorial Sloan-Kettering Cancer Center

Colorectal Surgery

  • Melissa Alvarez-Downing, MD
    Cleveland Clinic, Florida

Pediatric Surgery

  • Manish Raiji, MD
    University of Chicago


Class Starting in 2019

Class Starting in 2018

Class Starting in 2017

Class Starting in 2016

Class Starting in 2015


  1. The Changing Paradigm of Management of Liver Abscesses in Chronic Granulomatous DiseaseStraughan DM, McLoughlin KC, Mullinax JE, Marcinano BE, Freeman AF, Anderson VL, Uzel G, Azoury SC, Sorber R, Quadri H, Malech HL, DeRavin SS, Kamal N, Koh C, Zerbe CS, Kuhns DB, Gallin JI, Heller T, Holland SM, Rudloff U. Clin. Infect. Dis. 2017 Nov 4. doi: 10.1093/cid/cix1012. [Epub ahead of print]
  2. Biology is king and continues to rule.  McLoughlin KC, Goldin JW, Ripley RT. J Thorac Cardiovasc Surg. 2017 Oct;154(4):1448-1449. doi: 10.1016/j.jtcvs.2017.07.047. Epub 2017 Aug 4. No abstract available.
  3. Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies. Chen D, Yang J. Transl Res. 2017 Sep;187:11-21. doi: 10.1016/j.trsl.2017.05.006. Epub 2017 Jun 1.
  4. ASXL3 is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.  Shukla V, Rao M, Zhang H, Beers J, Wangsa D, Wangsa D, Buishand FO, Wang Y, Yu Z, Stevenson H, Reardon E, McLoughlin KC, Kaufman A, Payabyab E, Hong JA, Zhang M, Davis SR, Edelman DC, Chen G, Miettinen M, Restifo N, Ried T, Meltzer PS, Schrump DS. Cancer Res. 2017 Sep 21. pii: canres.0570.2017. doi: 10.1158/0008-5472.CAN-17-0570. [Epub ahead of print]
  5. Identification of essential genes for cancer immunotherapy.  Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP. Nature. 2017 Aug 31;548(7669):537-542. doi: 10.1038/nature23477. Epub 2017 Aug 7.
  6. Looks aren't everything, but neither is microRNA profiling.  McLoughlin KC, Ripley RT. J Thorac Cardiovasc Surg. 2017 Aug;154(2):728-729. doi: 10.1016/j.jtcvs.2017.03.092. Epub 2017 Apr 2. No abstract available.
  7. EGFR mutational status in lung adenocarcinoma: Staging implications or continuous evolution? Lo WM, Ripley RT. J Thorac Cardiovasc Surg. 2017 Aug 14. pii: S0022-5223(17)31706-3. doi: 10.1016/j.jtcvs.2017.07.053. [Epub ahead of print]
  8. Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer.  Quadri HS, Aiken TJ, Allgaeuer M, Moravec R, Altekruse S, Hussain SP, Miettinen MM, Hewitt SM, Rudloff U. BMC Cancer. 2017 Jul 21;17(1):495. doi: 10.1186/s12885-017-3481-4.
  9. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.  Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, Wunderlich JR, Danforth DN, Zlott D, Paria BC, Sabesan AC, Srivastava AK, Xi L, Pham TH, Raffeld M, White DE, Toomey MA, Rosenberg SA, Kammula US. Lancet Oncol. 2017 Jun;18(6):792-802. doi: 10.1016/S1470-2045(17)30251-6. Epub 2017 Apr 7.
  10. Targeting the epigenome in malignant pleural mesothelioma.  McLoughlin KC, Kaufman AS, Schrump DS. Transl Lung Cancer Res. 2017 Jun;6(3):350-365. doi: 10.21037/tlcr.2017.06.06. Review.
  11. Novel "Elements" of Immune Suppression within the Tumor Microenvironment.  Gurusamy D, Clever D, Eil R, Restifo NP. Cancer Immunol Res. 2017 Jun;5(6):426-433. doi: 10.1158/2326-6066.CIR-17-0117. Review.
  12. Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.  Chen I, Mathews-Greiner L, Li D, Abisoye-Ogunniyan A, Ray S, Bian Y, Shukla V, Zhang X, Guha R, Thomas C, Gryder B, Zacharia A, Beane JD, Ravichandran S, Ferrer M, Rudloff U. J Transl Med. 2017 May 1;15(1):92. doi: 10.1186/s12967-017-1197-5.
  13. Clinical nomograms: Is a picture worth a thousand words? McLoughlin KC, Ripley RT. J Thorac Cardiovasc Surg. 2017 Feb;153(2):470-471. doi: 10.1016/j.jtcvs.2016.11.002. Epub 2016 Nov 11.
  14. Adjuvant intraperitoneal chemotherapy for the treatment of gastric cancer at risk for peritoneal carcinomatosis: A systematic review.  Feingold PL, Kwong ML, Davis JL, Rudloff U. J Surg Oncol. 2017 Feb;115(2):192-201. doi: 10.1002/jso.24476. Epub 2016 Nov 23. Review.
  15. A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.  Deniger DC, Kwong ML, Pasetto A, Dudley ME, Wunderlich JR, Langhan MM, Lee CR, Rosenberg SA. Clin Cancer Res. 2017 Jan 15;23(2):351-362. doi: 10.1158/1078-0432.CCR-16-0906. Epub 2016 Oct 7.
  16. Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction.  Cruz AC, Ramaswamy M, Ouyang C, Klebanoff CA, Sengupta P, Yamamoto TN, Meylan F, Thomas SK, Richoz N, Eil R, Price S, Casellas R, Rao VK, Lippincott-Schwartz J, Restifo NP, Siegel RM. Nat Commun. 2016 Dec 23;7:13895. doi: 10.1038/ncomms13895
  17. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA. N Engl J Med. 2016 Dec 8;375(23):2255-2262.
  18. Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma.  Xi L, Pham TH, Payabyab EC, Sherry RM, Rosenberg SA, Raffeld M. Clin Cancer Res. 2016 Nov 15;22(22):5480-5486. doi: 10.1158/1078-0432.CCR-16-0613. Epub 2016 Aug 1.
  19. Thoracic Surgery in Chronic Granulomatous Disease: a 25-Year Single-Institution Experience.  Feingold PL, Quadri HS, Steinberg SM, Malech HL, Gallin JI, Zerbe CS, Zarember KA, Marciano BE, Holland SM, Schrump DS, Ripley RT.  J Clin Immunol. 2016 Oct;36(7):677-83. doi: 10.1007/s10875-016-0319-9. Epub 2016 Aug 6.
  20. Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor.  Pasetto A, Gros A, Robbins PF, Deniger DC, Prickett TD, Matus-Nicodemos R, Douek DC, Howie B, Robins H, Parkhurst MR, Gartner J, Trebska-McGowan K, Crystal JS, Rosenberg SA.  Cancer Immunol Res. 2016 Sep 2;4(9):734-43. doi: 10.1158/2326-6066.CIR-16-0001. Epub 2016 Jun 28.
  21. Ionic immune suppression within the tumour microenvironment limits T cell effector function.  Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, Palmer DC, Gros A, Yamamoto TN, Patel SJ, Guittard GC, Yu Z, Carbonaro V, Okkenhaug K, Schrump DS, Linehan WM, Roychoudhuri R, Restifo NP.  Nature. 2016 Sep 22;537(7621):539-543. doi: 10.1038/nature19364. Epub 2016 Sep 14.
  22. β-Catenin activation in fundic gland polyps, gastric cancer and colonic polyps in families afflicted by 'gastric adenocarcinoma and proximal polyposis of the stomach' (GAPPS).  McDuffie LA, Sabesan A, Allgäeuer M, Xin L, Koh C, Heller T, Davis JL, Raffeld M, Miettienen M, Quezado M, Rudloff U.  J Clin Pathol. 2016 Sep;69(9):826-33. doi: 10.1136/jclinpath-2016-203746. Epub 2016 Jul 12.
  23. Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche.  Clever D, Roychoudhuri R, Constantinides MG, Askenase MH, Sukumar M, Klebanoff CA, Eil RL, Hickman HD, Yu Z, Pan JH, Palmer DC, Phan AT, Goulding J, Gattinoni L, Goldrath AW, Belkaid Y, Restifo NP.  Cell. 2016 Aug 25;166(5):1117-1131.e14. doi: 10.1016/j.cell.2016.07.032.
  24. Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens.  Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ, Yao X, Wang R, Gros A, Li YF, El-Gamil M, Trebska-McGowan K, Rosenberg SA, Robbins PF.  Cancer Immunol Res. 2016 Aug;4(8):669-78. doi: 10.1158/2326-6066.CIR-15-0215. Epub 2016 Jun 16.
  25. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.  Goff SL, Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong ML, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, Rosenberg SA.  J Clin Oncol. 2016 Jul 10;34(20):2389-97. doi: 10.1200/JCO.2016.66.7220. Epub 2016 May 23.
  26. Significance of preoperative radiographic pancreatic density in predicting pancreatic fistula after surgery for pancreatic neuroendocrine tumorsAssadipour Y, Azoury SC, Schaub NN, Hong Y, Eil R, Inchauste SM, Steinberg SM, Venkatesan AM, Libutti SK, Hughes MS. Am J Surg.  2016 Jul;212(1):40-6. doi: 10.1016/j.amjsurg.2015.07.031. Epub 2015 Dec 12.
  27. Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape.  Crompton JG, Narayanan M, Cuddapah S, Roychoudhuri R, Ji Y, Yang W, Patel SJ, Sukumar M, Palmer DC, Peng W, Wang E, Marincola FM, Klebanoff CA, Zhao K, Tsang JS, Gattinoni L, Restifo NP.  Cell Mol Immunol. 2016 Jul;13(4):502-13. doi: 10.1038/cmi.2015.32. Epub 2015 Apr 27.
  28. BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers.  Roychoudhuri R, Clever D, Li P, Wakabayashi Y, Quinn KM, Klebanoff CA, Ji Y, Sukumar M, Eil RL, Yu Z, Spolski R, Palmer DC, Pan JH, Patel SJ, Macallan DC, Fabozzi G, Shih HY, Kanno Y, Muto A, Zhu J, Gattinoni L, O'Shea JJ, Okkenhaug K, Igarashi K, Leonard WJ, Restifo NP.  Nat Immunol. 2016 Jul;17(7):851-860. doi: 10.1038/ni.3441. Epub 2016 May 9.
  29. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).  Azoury SC, Gilmore RC, Shukla V.  Discov Med. 2016 Jun;21(118):507-16.
  30. Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin.  Xin HW, Ambe CM, Miller TC, Chen JQ, Wiegand GW, Anderson AJ, Ray S, Mullinax JE, Hari DM, Koizumi T, Godbout JD, Goldsmith PK, Stojadinovic A, Rudloff U, Thorgeirsson SS, Avital I.  J Cancer. 2016 Jun 6;7(9):1142-51. doi: 10.7150/jca.10047. eCollection 2016.
  31. MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases.  Kerkar SP, Wang ZF, Lasota J, Park T, Patel K, Groh E, Rosenberg SA, Miettinen MM.  J Immunother. 2016 May;39(4):181-7. doi: 10.1097/CJI.0000000000000119.
  32. Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.  Rothermel LD, Sabesan AC, Stephens DJ, Chandran SS, Paria BC, Srivastava AK, Somerville R, Wunderlich JR, Lee CC, Xi L, Pham TH, Raffeld M, Jailwala P, Kasoji M, Kammula US.  Clin Cancer Res. 2016 May 1;22(9):2237-49. doi: 10.1158/1078-0432.CCR-15-2294. Epub 2015 Dec 28.
  33. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.  Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA. Nat Med. 2016 Apr;22(4):433-8. doi: 10.1038/nm.4051. Epub 2016 Feb 22.
  34. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells. Rao M, Atay SM, Shukla V, Hong Y, Upham T, Ripley RT, Hong JA, Zhang M, Reardon E, Fetsch P, Miettinen M, Li X, Peer CJ, Sissung T, Figg WD, De Rienzo A, Bueno R, Schrump DS. Clin Cancer Res. 2016 Mar 1;22(5):1197-210. doi: 10.1158/1078-0432.CCR-14-3379. Epub 2015 Oct 12.
  35. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies: is it time?  Feingold PL, Kwong ML, Sabesan A, Sorber R, Rudloff U.  J Gastrointest Oncol. 2016 Feb;7(1):87-98. doi: 10.3978/j.issn.2078-6891.2015.098. Review.
  36. Prospective evaluation and treatment of familial carcinoid small intestine neuroendocrine tumors (SI-NETs).  Hughes MS, Azoury SC, Assadipour Y, Straughan DM, Trivedi AN, Lim RM, Joy G, Voellinger MT, Tang DM, Venkatesan AM, Chen CC, Louie A, Quezado MM, Forbes J, Wank SA.  Surgery. 2016 Jan;159(1):350-6. doi: 10.1016/j.surg.2015.05.041. Epub 2015 Oct 9.
  37. Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy.  Sukumar M, Liu J, Mehta GU, Patel SJ, Roychoudhuri R, Crompton JG, Klebanoff CA, Ji Y, Li P, Yu Z, Whitehill GD, Clever D, Eil RL, Palmer DC, Mitra S, Rao M, Keyvanfar K, Schrump DS, Wang E, Marincola FM, Gattinoni L, Leonard WJ, Muranski P, Finkel T, Restifo NP.  Cell Metab. 2016 Jan 12;23(1):63-76. doi: 10.1016/j.cmet.2015.11.002. Epub 2015 Dec 8.
  38. Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers.  Park TS, Groh EM, Patel K, Kerkar SP, Lee CC, Rosenberg SA.  J Immunother. 2016 Jan;39(1):1-7. doi: 10.1097/CJI.0000000000000101.
  39. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.  Azoury SC, Straughan DM, Shukla V.  Curr Cancer Drug Targets. 2015;15(6):452-62. Review.
  40. Targeting Akt in cell transfer immunotherapy for cancer.  Crompton JG, Sukumar M, Restifo NP.  Oncoimmunology. 2015 Dec 29;5(9):e1014776. eCollection 2016.
  41. Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome.  Aufforth RD, Ramakant P, Sadowski SM, Mehta A, Trebska-McGowan K, Nilubol N, Pacak K, Kebebew E.  J Clin Endocrinol Metab. 2015 Dec;100(12):4498-504. doi: 10.1210/jc.2015-3045. Epub 2015 Oct 9.
  42. Multidisciplinary management of locally advanced and widely metastatic paraganglioma in a patient with life-threatening compressive symptoms.  Neychev V, Straughan D, Pacak K, Kebebew E. Head Neck. 2015 Dec;37(12):E205-8. doi: 10.1002/hed.24069. Epub 2015 Jun 15.
  43. Landscape of Tumor Antigens in T Cell Immunotherapy.  Ilyas S, Yang JC. J. Immunol. 2015 Dec 1;195(11):5117-22. doi: 10.4049/jimmunol.1501657
  44. Quantitative reverse transcription polymerase chain reaction-based detection of thyroid-specific gene expression in fine-needle aspirate for thyroid cancer recurrence evaluation: a case report and review of the literature.  Azoury SC, Aufforth R, He M, Yang Z, Nilubol N, Kebebew E.  Head Neck. 2015 Nov;37(11):E165-8. doi: 10.1002/hed.24054. Epub 2015 Jul 14. Review.
  45. Pulmonary Metastases Exhibit Epigenetic Clonality: Implications for Precision Cancer Therapy.  Reardon ES, Hong JA, Straughan DM, Azoury SC, Zhang M, Schrump DS.  Ann Thorac Surg. 2015 Nov;100(5):1839-48; discussion 1848. doi: 10.1016/j.athoracsur.2015.05.089. Epub 2015 Aug 20.
  46. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance.  Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, Ji Y, Van Panhuys N, Klebanoff CA, Sukumar M, Clever D, Chichura A, Roychoudhuri R, Varma R, Wang E, Gattinoni L, Marincola FM, Balagopalan L, Samelson LE, Restifo NP.  J Exp Med. 2015 Nov 16;212(12):2095-113. doi: 10.1084/jem.20150304. Epub 2015 Nov 2.
  47. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.  Draper LM, Kwong ML, Gros A, Stevanović S, Tran E, Kerkar S, Raffeld M, Rosenberg SA, Hinrichs CS.  Clin Cancer Res. 2015 Oct 1;21(19):4431-9. doi: 10.1158/1078-0432.CCR-14-3341.
  48. Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.  Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ, Kammula US.  Cancer Res. 2015 Aug 15;75(16):3216-26. doi: 10.1158/0008-5472.CAN-15-0584. Epub 2015 Jun 22.
  49. Preoperative Imaging Features are Associated with Surgical Complications Following Carotid Body Tumor Resection.  Straughan DM, Neychev VK, Sadowski SM, Ellis RJ, Thomas F, Patronas NJ, Pacak K, Kebebew E, Nilubol N. World J Surg. 2015 Aug;39(8):2084-9. doi: 10.1007/s00268-015-3058-9.
  50. Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.  Beane JD, Lee G, Zheng Z, Mendel M, Abate-Daga D, Bharathan M, Black M, Gandhi N, Yu Z, Chandran S, Giedlin M, Ando D, Miller J, Paschon D, Guschin D, Rebar EJ, Reik A, Holmes MC, Gregory PD, Restifo NP, Rosenberg SA, Morgan RA, Feldman SA.  Mol Ther. 2015 Aug;23(8):1380-1390. doi: 10.1038/mt.2015.71. Epub 2015 May 5.
  51. Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.  Feldman SA, Assadipour Y, Kriley I, Goff SL, Rosenberg SA.  Semin Oncol. 2015 Aug;42(4):626-39. doi: 10.1053/j.seminoncol.2015.05.005. Epub 2015 Jun 12. Review.
  52. Pulmonary mucosa-associated lymphoma in a patient with von Hippel-Lindau disease.  Straughan DM, Kerkar S, Azoury SC, Reardon ES, Schrump DS.  J Surg Case Rep. 2015 Jul 14;2015(7). pii: rjv080. doi: 10.1093/jscr/rjv080.
  53. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma.  Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ, Hughes MS, Kammula US, Feldman SA, Toomey MA, Kerkar SP, Restifo NP, Yang JC, Rosenberg SA.  Clin Cancer Res. 2015 May 15;21(10):2278-88. doi: 10.1158/1078-0432.CCR-14-2085. Epub 2015 Feb 18.
  54. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.  Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS.  J Clin Oncol. 2015 May 10;33(14):1543-50. doi: 10.1200/JCO.2014.58.9093. Epub 2015 Mar 30.
  55. Unknown primary nasopharyngeal melanoma presenting as severe recurrent epistaxis and hearing loss following treatment and remission of metastatic disease: A case report and literature review.  Azoury SC, Crompton JG, Straughan DM, Klemen ND, Reardon ES, Beresnev TH, Hughes MS.  Int J Surg Case Rep. 2015;10:232-5. doi: 10.1016/j.ijscr.2015.03.053. Epub 2015 Apr 1.
  56. The interplay of effector and regulatory T cells in cancer.  Roychoudhuri R, Eil RL, Restifo NP.  Curr Opin Immunol. 2015 Apr;33:101-11. doi: 10.1016/j.coi.2015.02.003. Epub 2015 Feb 27. Review.
  57. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.  Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA.  Clin Cancer Res. 2015 Mar 1;21(5):1019-27. doi: 10.1158/1078-0432.CCR-14-2708. Epub 2014 Dec 23.
  58. Surgery for Li Fraumeni syndrome: pushing the limits of surgical oncology.  Langan RC, Lagisetty KH, Atay S, Pandalai P, Stojadinovic A, Rudloff U, Avital I.  Am J Clin Oncol. 2015 Feb;38(1):98-102. doi: 10.1097/COC.0b013e3182880bc5.
  59. Editorial commentary: Esophageal complications: what are the real results?  Taylor Ripley R, Reardon ESSemin Thorac Cardiovasc Surg. 2014 Winter;26(4):295-6. doi: 10.1053/j.semtcvs.2015.03.002. Epub 2015 Mar 14.
  60. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.  Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ, Dudley ME, Somerville R, Wunderlich JR, Sherry RM, Yang JC, Rosenberg SA, Kammula US.  Clin Cancer Res. 2015 Feb 1;21(3):534-43. doi: 10.1158/1078-0432.CCR-14-2208. Epub 2014 Nov 25.
  61. Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study.  Beane JD, Griffin KF, Levy EB, Pandalai P, Wood B, Abi-Jaoudeh N, Beresnev T, Shutack Y, Webb CC, Avital I, Rudloff U. Invest New Drugs. 2015 Feb;33(1):109-18. doi: 10.1007/s10637-014-0157-7. Epub 2014 Sep 19.
  62. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.  Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, Tran E, Hanada K, Yu Z, Palmer DC, Kerkar SP, Michalek RD, Upham T, Leonardi A, Acquavella N, Wang E, Marincola FM, Gattinoni L, Muranski P, Sundrud MS, Klebanoff CA, Rosenberg SA, Fearon DT, Restifo NP.  Cancer Res. 2015 Jan 15;75(2):296-305. doi: 10.1158/0008-5472.CAN-14-2277. Epub 2014 Nov 28.
  63. Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.  Acquavella N, Clever D, Yu Z, Roelke-Parker M, Palmer DC, Xi L, Pflicke H, Ji Y, Gros A, Hanada K, Goldlust IS, Mehta GU, Klebanoff CA, Crompton JG, Sukumar M, Morrow JJ, Franco Z, Gattinoni L, Liu H, Wang E, Marincola F, Stroncek DF, Lee CC, Raffeld M, Bosenberg MW, Roychoudhuri R, Restifo NP.  Cancer Immunol Res. 2015 Jan;3(1):37-47. doi: 10.1158/2326-6066.CIR-14-0122. Epub 2014 Oct 30.
  64. A complicated case of vascular Pythium insidiosum infection treated with limb-sparing surgery.  Pan JH, Kerkar SP, Siegenthaler MP, Hughes M, Pandalai PK. Int J Surg Case Rep. 2014;5(10):677-80. doi: 10.1016/j.ijscr.2014.05.018. Epub 2014 Aug 1.
  65. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.  Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I.  J Surg Oncol. 2014 Sep;110(3):275-84. doi: 10.1002/jso.23633. Epub 2014 Jul 5.
  66. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.  Beard RE, Zheng Z, Lagisetty KH, Burns WR, Tran E, Hewitt SM, Abate-Daga D, Rosati SF, Fine HA, Ferrone S, Rosenberg SA, Morgan RA.  J Immunother Cancer. 2014 Aug 19;2:25. doi: 10.1186/2051-1426-2-25. eCollection 2014.
  67. Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial.  Beane JD, Yang JC, White D, Steinberg SM, Rosenberg SA, Rudloff U.  Ann Surg Oncol. 2014 Aug;21(8):2484-9. doi: 10.1245/s10434-014-3732-4. Epub 2014 Apr 23.
  68. Telomerase variant A279T induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal carcinomas.  Zhang Y, Calado R, Rao M, Hong JA, Meeker AK, Dumitriu B, Atay S, McCormick PJ, Garfield SH, Wangsa D, Padilla-Nash HM, Burkett S, Zhang M, Kunst TF, Peterson NR, Xi S, Inchauste S, Altorki NK, Casson AG, Beer DG, Harris CC, Ried T, Young NS, Schrump DS.  PLoS One. 2014 Jul 1;9(7):e101010. doi: 10.1371/journal.pone.0101010. eCollection 2014.
  69. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.  Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF. Clin Cancer Res. 2014 Jul 1;20(13):3401-10. doi: 10.1158/1078-0432.CCR-14-0433.
  70. A systematic review and pooled analysis of CPR-associated cardiovascular and thoracic injuries. Miller AC, Rosati SF, Suffredini AF, Schrump DS. Resuscitation. 2014 Jun;85(6):724-31. doi: 10.1016/j.resuscitation.2014.01.028. Epub 2014 Feb 10. Review.
  71. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation.  Tseng J, Citrin DE, Waldman M, White DE, Rosenberg SA, Yang JC. Cancer. 2014 May 1;120(9):1426-32. doi: 10.1002/cncr.28547. Epub 2014 Jan 28.
  72. A novel murine T-cell receptor targeting NY-ESO-1. Rosati SF, Parkhurst MR, Hong Y, Zheng Z, Feldman SA, Rao M, Abate-Daga D, Beard RE, Xu H, Black MA, Robbins PF, Schrump DA, Rosenberg SA, Morgan RA. J Immunother. 2014 Apr;37(3):135-46. doi: 10.1097/CJI.0000000000000019.
  73. Reprogramming antitumor immunity.  Crompton JG, Clever D, Vizcardo R, Rao M, Restifo NP.  Trends Immunol. 2014 Apr;35(4):178-85. doi: 10.1016/ Epub 2014 Mar 21. Review.
  74. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.  Crompton JG, Sukumar M, Restifo NP.  Immunol Rev. 2014 Jan;257(1):264-276. doi: 10.1111/imr.12135. Review.
  75. Label-retaining liver cancer cells are relatively resistant to sorafenib.  Xin HW, Ambe CM, Hari DM, Wiegand GW, Miller TC, Chen JQ, Anderson AJ, Ray S, Mullinax JE, Koizumi T, Langan RC, Burka D, Herrmann MA, Goldsmith PK, Stojadinovic A, Rudloff U, Thorgeirsson SS, Avital I.  Gut. 2013 Dec;62(12):1777-86. doi: 10.1136/gutjnl-2012-303261. Epub 2013 Feb 14.
  76. Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy.  Kwong ML, Neyns B, Yang JC.  Clin Cancer Res. 2013 Oct 1;19(19):5292-9. doi: 10.1158/1078-0432.CCR-13-0261. Review.
  77. Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy.  Beard RE, Abate-Daga D, Rosati SF, Zheng Z, Wunderlich JR, Rosenberg SA, Morgan RA. Clin Cancer Res. 2013 Sep 15;19(18):4941-50. doi: 10.1158/1078-0432.CCR-13-1253. Epub 2013 Sep 10.
  78. Collapse of the tumor stroma is triggered by IL-12 induction of Fas.  Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, Pan JH, Palmer DC, Morgan RA, Rosenberg SA, Restifo NP.  Mol Ther. 2013 Jul;21(7):1369-77. doi: 10.1038/mt.2013.58. Epub 2013 Apr 9.
  79. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis.  Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, Sciumè G, Zare H, Vahedi G, Dema B, Yu Z, Liu H, Takahashi H, Rao M, Muranski P, Crompton JG, Punkosdy G, Bedognetti D, Wang E, Hoffmann V, Rivera J, Marincola FM, Nakamura A, Sartorelli V, Kanno Y, Gattinoni L, Muto A, Igarashi K, O'Shea JJ, Restifo NP.  Nature. 2013 Jun 27;498(7455):506-10. doi: 10.1038/nature12199. Epub 2013 Jun 2.
  80. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.  Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA. J Clin Oncol. 2013 Jun 10;31(17):2152-9. doi: 10.1200/JCO.2012.46.6441. Epub 2013 May 6.
  81. Wnt and the cancer niche: paracrine interactions with gastrointestinal cancer cells undergoing asymmetric cell division.  Xin HW, Ambe CM, Ray S, Kim BK, Koizumi T, Wiegand GW, Hari D, Mullinax JE, Jaiswal KR, Garfield SH, Stojadinovic A, Rudloff U, Thorgeirsson SS, Avital I.  J Cancer. 2013 Jul 2;4(6):447-57. doi: 10.7150/jca.6896. Print 2013.
  82. The role of surgery in the management of patients with refractory chronic granulomatous disease colitis.  Alvarez-Downing MM, Kamal N, Inchauste SM, Khangura SK, Malech HL, Holland SM, Hughes MS, Heller T, Sherry RM.  Dis Colon Rectum. 2013 May;56(5):609-14. doi: 10.1097/DCR.0b013e3182781504.
  83. RTN4IP1 is down-regulated in thyroid cancer and has tumor-suppressive function.  Rahbari R, Kitano M, Zhang L, Bommareddi S, Kebebew E.  J Clin Endocrinol Metab. 2013 Mar;98(3):E446-54. doi: 10.1210/jc.2012-3180. Epub 2013 Feb 7.
  84. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA. J Immunother. 2013 Feb;36(2):133-51. doi: 10.1097/CJI.0b013e3182829903.
  85. Memoirs of a reincarnated T cell.  Crompton JG, Rao M, Restifo NP.  Cell Stem Cell. 2013 Jan 3;12(1):6-8. doi: 10.1016/j.stem.2012.12.009.
  86. A novel nomogram for peritoneal mesothelioma predicts survival.  Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I.  Ann Surg Oncol. 2013 Feb;20(2):555-61. doi: 10.1245/s10434-012-2651-5. Epub 2012 Dec 12.
  87. Aryl hydrocarbon receptor-induced adrenomedullin mediates cigarette smoke carcinogenicity in humans and mice.  Portal-Nuñez S, Shankavaram UT, Rao M, Datrice N, Atay S, Aparicio M, Camphausen KA, Fernández-Salguero PM, Chang H, Lin P, Schrump DS, Garantziotis S, Cuttitta F, Zudaire E.  Cancer Res. 2012 Nov 15;72(22):5790-800. doi: 10.1158/0008-5472.CAN-12-0818. Epub 2012 Sep 19.
  88. The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.  Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CC, Singh S, Li T, Dudley ME, Restifo NP, Rosenberg SA, Kammula US.  Sci Transl Med. 2012 Aug 29;4(149):149ra120. doi: 10.1126/scitranslmed.3004306.
  89. Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells.  Zhang M, Mathur A, Zhang Y, Xi S, Atay S, Hong JA, Datrice N, Upham T, Kemp CD, Ripley RT, Wiegand G, Avital I, Fetsch P, Mani H, Zlott D, Robey R, Bates SE, Li X, Rao M, Schrump DS.  Cancer Res. 2012 Aug 15;72(16):4178-92. doi: 10.1158/0008-5472.CAN-11-3983. Epub 2012 Jul 2.
  90. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.  Alvarez-Downing MM, Inchauste SM, Dudley ME, White DE, Wunderlich JR, Rosenberg SA, Kammula US.  World J Surg Oncol. 2012 Jun 22;10:113. doi: 10.1186/1477-7819-10-113.
  91. A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers.  Langan RC, Mullinax JE, Ray S, Raiji MT, Schaub N, Xin HW, Koizumi T, Steinberg SM, Anderson A, Wiegand G, Butcher D, Anver M, Bilchik AJ, Stojadinovic A, Rudloff U, Avital I.  J Cancer. 2012;3:231-40. doi: 10.7150/jca.4542. Epub 2012 Jun 1.
  92. Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 years.  Neary NM, Lopez-Chavez A, Abel BS, Boyce AM, Schaub N, Kwong K, Stratakis CA, Moran CA, Giaccone G, Nieman LK.  J Clin Endocrinol Metab. 2012 Jul;97(7):2223-30. doi: 10.1210/jc.2011-3355. Epub 2012 Apr 16.
  93. Establishment of human ultra-low passage colorectal cancer cell lines using spheroids from fresh surgical specimens suitable for in vitro and in vivo studies.  Ray S, Langan RC, Mullinax JE, Koizumi T, Xin HW, Wiegand GW, Anderson AJ, Stojadinovic A, Thorgeirsson S, Rudloff U, Avital I.  J Cancer. 2012;3:196-206. doi: 10.7150/jca.4484. Epub 2012 May 7.
  94. Tumor-initiating label-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division.  Xin HW, Hari DM, Mullinax JE, Ambe CM, Koizumi T, Ray S, Anderson AJ, Wiegand GW, Garfield SH, Thorgeirsson SS, Avital I.  Stem Cells. 2012 Apr;30(4):591-8. doi: 10.1002/stem.1061.
  95. Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples.  Kitano M, Rahbari R, Patterson EE, Steinberg SM, Prasad NB, Wang Y, Zeiger MA, Kebebew E.  Thyroid. 2012 Mar;22(3):285-91. doi: 10.1089/thy.2011.0313. Epub 2012 Feb 3.
  96. Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.  Kitano M, Millo C, Rahbari R, Herscovitch P, Gesuwan K, Webb RC, Venkatesan AM, Phan GQ, Hughes MS, Libutti SK, Nilubol N, Linehan WM, Kebebew E.  Surgery. 2011 Dec;150(6):1122-8. doi: 10.1016/j.surg.2011.09.048.
  97. Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs.  Kitano M, Rahbari R, Patterson EE, Xiong Y, Prasad NB, Wang Y, Zeiger MA, Kebebew E. Ann Surg Oncol. 2011 Nov;18(12):3443-52. doi: 10.1245/s10434-011-1766-4. Epub 2011 May 7.
  98. CDC23 regulates cancer cell phenotype and is overexpressed in papillary thyroid cancer.  Zhang L, Rahbari R, He M, Kebebew E.  Endocr Relat Cancer. 2011 Nov 28;18(6):731-42. doi: 10.1530/ERC-11-0181. Print 2011.
  99. Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study.  Mathur A, Moses W, Rahbari R, Khanafshar E, Duh QY, Clark O, Kebebew E. Cancer. 2011 Oct 1;117(19):4390-5. doi: 10.1002/cncr.26072. Epub 2011 Mar 15.
  100. Identification of differentially expressed microRNA in parathyroid tumors.  Rahbari R, Holloway AK, He M, Khanafshar E, Clark OH, Kebebew E.  Ann Surg Oncol. 2011 Apr;18(4):1158-65. doi: 10.1245/s10434-010-1359-7. Epub 2010 Nov 18.
  101. Prospective randomized trial of ligasure versus harmonic hemostasis technique in thyroidectomy.  Rahbari R, Mathur A, Kitano M, Guerrero M, Shen WT, Duh QY, Clark OH, Kebebew E.  Ann Surg Oncol. 2011 Apr;18(4):1023-7. doi: 10.1245/s10434-010-1251-5. Epub 2010 Nov 12.
  102. Laparoscopic appendectomy for Amyand's hernia: a modern approach to a historic diagnosis.  Mullinax JE, Allins A, Avital I.  J Gastrointest Surg. 2011 Mar;15(3):533-5. doi: 10.1007/s11605-010-1386-5. Epub 2010 Nov 11.
  103. A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy.  Mathur A, Weng J, Moses W, Steinberg SM, Rahbari R, Kitano M, Khanafshar E, Ljung BM, Duh QY, Clark OH, Kebebew E.  Surgery. 2010 Dec;148(6):1170-6; discussion 1176-7. doi: 10.1016/j.surg.2010.09.025.
  104. Thyroid cancer gender disparity.  Rahbari R, Zhang L, Kebebew E.  Future Oncol. 2010 Nov;6(11):1771-9. doi: 10.2217/fon.10.127. Review.
  105. Prior head and neck radiation exposure is not a contraindication to minimally invasive parathyroidectomy.  Rahbari R, Sansano IG, Elaraj DM, Duh QY, Clark OH, Kebebew E.  J Am Coll Surg. 2010 Jun;210(6):942-8. doi: 10.1016/j.jamcollsurg.2010.02.041.
  • Fellow with scientific poster
  • Surgical Team in the OR
  • The OR setup with equipment
  • Patient's Eye View of the Surgical Team
  • Dr.  Davis with a fellow in the OR.
  • Meeting in a board room.
  • Samantha Ruff with a scientific poster
  • Dr. Davis with fellows at the Society of Surgical Oncology 2018 Annual Cancer Symposium
  • Fellows group photo in lab coats